Properdin: A Novel Target for Neuroprotection in Neonatal Hypoxic-Ischemic Brain Injury

Background: Hypoxic-ischemic (HI) encephalopathy is a major cause of neonatal mortality and morbidity, with a global incidence of 3 per 1,000 live births. Intrauterine or perinatal complications, including maternal infection, constitute a major risk for the development of neonatal HI brain damage. D...

Full description

Bibliographic Details
Main Authors: Claudia Sisa, Qudsiyah Agha-Shah, Balpreet Sanghera, Ariela Carno, Cordula Stover, Mariya Hristova
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-11-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.02610/full
_version_ 1818337900409913344
author Claudia Sisa
Qudsiyah Agha-Shah
Balpreet Sanghera
Ariela Carno
Cordula Stover
Mariya Hristova
author_facet Claudia Sisa
Qudsiyah Agha-Shah
Balpreet Sanghera
Ariela Carno
Cordula Stover
Mariya Hristova
author_sort Claudia Sisa
collection DOAJ
description Background: Hypoxic-ischemic (HI) encephalopathy is a major cause of neonatal mortality and morbidity, with a global incidence of 3 per 1,000 live births. Intrauterine or perinatal complications, including maternal infection, constitute a major risk for the development of neonatal HI brain damage. During HI, inflammatory response and oxidative stress occur, causing subsequent cell death. The presence of an infection sensitizes the neonatal brain, making it more vulnerable to the HI damage. Currently, therapeutic hypothermia is the only clinically approved treatment available for HI encephalopathy, however it is only partially effective in HI alone and its application in infection-sensitized HI is debatable. Therefore, there is an unmet clinical need for the development of novel therapeutic interventions for the treatment of HI. Such an alternative is targeting the complement system. Properdin, which is involved in stabilization of the alternative pathway convertases, is the only known positive regulator of alternative complement activation. Absence of the classical pathway in the neonatal HI brain is neuroprotective. However, there is a paucity of data on the participation of the alternative pathway and in particular the role of properdin in HI brain damage.Objectives: Our study aimed to validate the effect of global properdin deletion in two mouse models: HI alone and LPS-sensitized HI, thus addressing two different clinical scenarios.Results: Our results indicate that global properdin deletion in a Rice-Vannucci model of neonatal HI and LPS-sensitized HI brain damage, in the short term, clearly reduced forebrain cell death and microglial activation, as well as tissue loss. In HI alone, deletion of properdin reduced TUNEL+ cell death and microglial post-HI response at 48 h post insult. Under the conditions of LPS-sensitized HI, properdin deletion diminished TUNEL+ cell death, tissue loss and microglial activation at 48 h post-HI.Conclusion: Overall, our data suggests a critical role for properdin, and possibly also a contribution in neonatal HI alone and in infection-sensitized HI brain damage. Thus, properdin can be considered a novel target for treatment of neonatal HI brain damage.
first_indexed 2024-12-13T15:02:34Z
format Article
id doaj.art-c4b4404ffb224b15826dfe2dbc2d90a3
institution Directory Open Access Journal
issn 1664-3224
language English
last_indexed 2024-12-13T15:02:34Z
publishDate 2019-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj.art-c4b4404ffb224b15826dfe2dbc2d90a32022-12-21T23:41:06ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-11-011010.3389/fimmu.2019.02610463302Properdin: A Novel Target for Neuroprotection in Neonatal Hypoxic-Ischemic Brain InjuryClaudia Sisa0Qudsiyah Agha-Shah1Balpreet Sanghera2Ariela Carno3Cordula Stover4Mariya Hristova5Perinatal Brain Repair Group, UCL Institute for Women's Health, Maternal & Fetal Medicine, London, United KingdomPerinatal Brain Repair Group, UCL Institute for Women's Health, Maternal & Fetal Medicine, London, United KingdomPerinatal Brain Repair Group, UCL Institute for Women's Health, Maternal & Fetal Medicine, London, United KingdomPerinatal Brain Repair Group, UCL Institute for Women's Health, Maternal & Fetal Medicine, London, United KingdomDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester, United KingdomPerinatal Brain Repair Group, UCL Institute for Women's Health, Maternal & Fetal Medicine, London, United KingdomBackground: Hypoxic-ischemic (HI) encephalopathy is a major cause of neonatal mortality and morbidity, with a global incidence of 3 per 1,000 live births. Intrauterine or perinatal complications, including maternal infection, constitute a major risk for the development of neonatal HI brain damage. During HI, inflammatory response and oxidative stress occur, causing subsequent cell death. The presence of an infection sensitizes the neonatal brain, making it more vulnerable to the HI damage. Currently, therapeutic hypothermia is the only clinically approved treatment available for HI encephalopathy, however it is only partially effective in HI alone and its application in infection-sensitized HI is debatable. Therefore, there is an unmet clinical need for the development of novel therapeutic interventions for the treatment of HI. Such an alternative is targeting the complement system. Properdin, which is involved in stabilization of the alternative pathway convertases, is the only known positive regulator of alternative complement activation. Absence of the classical pathway in the neonatal HI brain is neuroprotective. However, there is a paucity of data on the participation of the alternative pathway and in particular the role of properdin in HI brain damage.Objectives: Our study aimed to validate the effect of global properdin deletion in two mouse models: HI alone and LPS-sensitized HI, thus addressing two different clinical scenarios.Results: Our results indicate that global properdin deletion in a Rice-Vannucci model of neonatal HI and LPS-sensitized HI brain damage, in the short term, clearly reduced forebrain cell death and microglial activation, as well as tissue loss. In HI alone, deletion of properdin reduced TUNEL+ cell death and microglial post-HI response at 48 h post insult. Under the conditions of LPS-sensitized HI, properdin deletion diminished TUNEL+ cell death, tissue loss and microglial activation at 48 h post-HI.Conclusion: Overall, our data suggests a critical role for properdin, and possibly also a contribution in neonatal HI alone and in infection-sensitized HI brain damage. Thus, properdin can be considered a novel target for treatment of neonatal HI brain damage.https://www.frontiersin.org/article/10.3389/fimmu.2019.02610/fullproperdincomplementalternative pathwayhypoxiaischemianeuroprotection
spellingShingle Claudia Sisa
Qudsiyah Agha-Shah
Balpreet Sanghera
Ariela Carno
Cordula Stover
Mariya Hristova
Properdin: A Novel Target for Neuroprotection in Neonatal Hypoxic-Ischemic Brain Injury
Frontiers in Immunology
properdin
complement
alternative pathway
hypoxia
ischemia
neuroprotection
title Properdin: A Novel Target for Neuroprotection in Neonatal Hypoxic-Ischemic Brain Injury
title_full Properdin: A Novel Target for Neuroprotection in Neonatal Hypoxic-Ischemic Brain Injury
title_fullStr Properdin: A Novel Target for Neuroprotection in Neonatal Hypoxic-Ischemic Brain Injury
title_full_unstemmed Properdin: A Novel Target for Neuroprotection in Neonatal Hypoxic-Ischemic Brain Injury
title_short Properdin: A Novel Target for Neuroprotection in Neonatal Hypoxic-Ischemic Brain Injury
title_sort properdin a novel target for neuroprotection in neonatal hypoxic ischemic brain injury
topic properdin
complement
alternative pathway
hypoxia
ischemia
neuroprotection
url https://www.frontiersin.org/article/10.3389/fimmu.2019.02610/full
work_keys_str_mv AT claudiasisa properdinanoveltargetforneuroprotectioninneonatalhypoxicischemicbraininjury
AT qudsiyahaghashah properdinanoveltargetforneuroprotectioninneonatalhypoxicischemicbraininjury
AT balpreetsanghera properdinanoveltargetforneuroprotectioninneonatalhypoxicischemicbraininjury
AT arielacarno properdinanoveltargetforneuroprotectioninneonatalhypoxicischemicbraininjury
AT cordulastover properdinanoveltargetforneuroprotectioninneonatalhypoxicischemicbraininjury
AT mariyahristova properdinanoveltargetforneuroprotectioninneonatalhypoxicischemicbraininjury